Anti-malignin antibody is a putative general antibody marker for malignant cancers, and the basis for a cancer screening test marketed by Oncolab of Boston, Mass. Initial claims for the effectiveness of the test emerged in the refereed literature in the mid-1990s.[1][2][3]

However, the diagnostic efficacy of the test, as determined by its sensitivity and specificity has since been disputed [4][5]

References

  1. ↑ Abrams M B et al Early detection and monitoring of cancer with the anti-malignin antibody test Cancer Detection & Prevention 1994 18(1):65-78 Archived 2016-03-04 at the Wayback Machine
  2. ↑ Botti C, Martinetti A, Nerini-Molteni S, Ferrari L (1997). "Anti-malignin antibody evaluation: a possible challenge for cancer management". Int. J. Biol. Markers. 12 (4): 141–7. doi:10.1177/172460089701200401. PMID 9582602. S2CID 13377112.
  3. ↑ Thornthwaite JT. Anti-malignin antibody in serum and other tumor marker determinations in breast cancer. Cancer Lett 2000;148:39–48
  4. ↑ Harman, S.M et al Discrimination of Breast Cancer by Anti-Malignin Antibody Serum Test in Women Undergoing Biopsy Cancer Epidemiology, Biomarkers & Prevention October 2005 14; 2310 doi: 10.1158/1055-9965.EPI-04-0802
  5. ↑ "Anti-Malignin Antibody -- A Screening Test for Cancer?".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.